Interview with Igor Krylov, CEO, Pharmstandard
You have lead this company since its beginnings in 2003, when it acquired ICN pharmaceuticals. In 2007, Pharmstandard carried out an IPO of 43% of its shares. How has the…
Address: Likhachevsky drive 5 «B», Moscow region, Dolgoprudny, 141700,Russia
Tel: +7 (495) 970-0030/32
Web: http://pharmstd.ru/
Pharmstandard is the leader of Russian pharmaceutical industry in R&D and production of the medicinal products.
In 2010, Pharmstandard became №2 among all pharmaceutical companies represented in Russia and market share reached 4.2%.1 Since 2007 Pharmstandard keeps its leading position in commercial segment and remains strong leader among the domestic pharmaceutical company-manufacturers.*1
Pharmstandard became the winner of the national business award ‘Company of the Year 2010’ according to RBC.*2
During the tenth anniversary of «Platinum Ounce 2010», the open competition among professionals of pharma business, Pharmstandard was awarded in the nominations for «The Company of the Year – the Russian pharmaceutical products manufacturer» and «The Company of Decade – the Russian pharmaceutical products manufacturer».
Pharmstandard operates four modern pharmaceutical manufacturing facilities: JSC «Pharmstandard-Leksredstva» in Kursk, JSC «Pharmstandard-UfaVITA» in Ufa, JSC «Pharmstandard-Tomskhimpharm» in Tomsk, PJSC «Pharmstandard-Biolek» in Kharkov (Ukraine) and medical equipment factory JSC «TZMOI» in Tyumen.
The Company has invested approximately RUR 3 billion RUR in modernization and development of production capacities reaching more than 1,35 bln units per year. All the production facilities fully comply with Russian manufacturing standards. Six production lines of JSC «Pharmstandard-Leksredstva» meet EU GMP requirements.
Pharmstandard portfolio includes over 250 products used in the treatment of diabetes, growth hormone deficiency, cardiovascular diseases, gastroenterological and neurological disorders, infectious diseases, cancer. More than 100 products offered by Pharmstandard are included in the List of Vital and Essential Pharmaceuticals.
In 2004-1H2011, we developed and introduced over 55 new pharmaceutical products in close collaboration with the leading scientific centers of Russia. Pharmstandard is the partner of the joint venture biotechnological project «Generium» in order to develop and manufacture innovative biological products within the state program of import substitution.
Pharmstandard became a public company on 4 may 2007 by offering to the public 27.57% of its share capital in the form of GDR on the London Stock Exchange (LSE) and 18.12% of its share capital in the form of ordinary shares on two local stock exchanges (RTS, MICEX). Approximately 54.31%of voting shares of OJSC «Pharmstandard» are held by «Augment Investments Limited».
www.pharmstd.ru
1 Pharmexpert (CMR) 2010 market data.
2 The annual national business award ‘Company of the Year’ is organized by RBK Holdings.
Pharmstandard portfolio includes over 250 products used in the treatment of diabetes, growth hormone deficiency, cardiovascular diseases, gastroenterological and neurological disorders, infectious diseases, cancer. More than 100 products offered by Pharmstandard are included in the List of Vital and Essential Pharmaceuticals.
You have lead this company since its beginnings in 2003, when it acquired ICN pharmaceuticals. In 2007, Pharmstandard carried out an IPO of 43% of its shares. How has the…
IMEDA was founded in 2005, and today counts amongst its members 28 leading international companies in the Russian medical technology sector. What are the main goals of the association today,…
When we first met, you mentioned that you assumed this position in 2009, to help UCB Russia recover from a flat spin in the wake of the financial crisis. What…
Merck KGaA describes itself as the world’s oldest pharmaceutical and chemicals company. What is the company’s history here in Russia? The Russian subsidiary was actually incorporated over 100 years ago.…
Ipsen has recently announced the acquisition of a Russian pharmaceutical license. Even before this license, Russia was already one of the largest affiliates. of the group, as of 2010. The…
What were the difficulties in the CIS regions around the time of the financial crisis? Were there similarities to the situation in Russia? Yes, the situation in the CIS was…
You have been with Boehringer Ingelheim since the early days of your career in 1994. In the pharmaceutical sector, managers seem to jump from company to company quite often—but you…
You were the former director of RMBC, which was acquired in 2008 by the IMS. How important was this acquisition in terms of positioning the IMS on the Russian market?…
Roche is the leading company in the ONLS (high-technology reimbursement) segment of the prescription drug market, and also the top oncology company in Russia. As the General Manager of the…
You have been in Russia now for a bit less than a year, having come from the former Schering-Plough’s Hungary office to run the Russian MSD affiliate. In our conversation…
Binnopharm was established in 2006, with 100% of charter capital coming from holding company JSFC Sistema. What was the vision behind the creation of Binnopharm? The company was indeed established…
Nycomed is currently constructing a Greenfield plant in the Yaroslavl region, at an investment of 75-80Mn EUR. Last time we met in 2006, many foreign companies viewed local production as…
Celegene did not have a Russian affiliate office during Focus Reports’ initial report on Russia in 2006. What attracted Celgene’s relatively recent entrance into this market? We had external and…
See our Cookie Privacy Policy Here
